ArticleInsights into imaging2026
Recurrent laryngeal nerve lymph nodes status prediction after neoadjuvant therapy for thoracic esophageal squamous cell carcinoma.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic significance of recurrent laryngeal nerve lymph node dissection in esophageal squamous cell carcinoma: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesAccurately predicting recurrent laryngeal nerve lymph nodes (RLNs) status after neoadjuvant therapy is challenging but essential for efficient dissection of RLNs and for lowering local recurrence rates in patients with esophageal cancer. MATERIALS AND
methodsIn this retrospective study, 403 patients diagnosed with esophageal squamous cell cancer between 2010 and 2021 were included and randomly divided into training and test cohorts at a ratio of 2:1. Logistic regression and least absolute shrinkage and selection operator (LASSO) regression analyses were conducted to identify significant factors associated with residual RLNs. Multivariable logistic regression analysis was used to develop the final nomogram by integrating clinical factors and pre- and post-treatment CT imaging features. The discriminatory ability of the nomogram was assessed using the area under the receiver operating characteristic (ROC) curve.
resultsThe RLN metastatic rate after neoadjuvant therapy was 13.2%. Significant predictors of RLN (+) status post-neoadjuvant therapy identified by LASSO regression analysis included neoadjuvant therapy plan, serum albumin level, long diameter of the primary lesion, baseline necrosis of RLNs, baseline long diameter of RLNs, and short diameter of RLNs post-neoadjuvant treatment. The nomogram demonstrated good discriminative ability, with an area under the ROC curve of 0.856 in the test set. Neoadjuvant chemoradiotherapy was associated with a 70% reduction in the rate of RLN residues compared to neoadjuvant chemotherapy alone.
conclusionThe nomogram, based on clinical factors and pre- and post-treatment CT imaging features, provides a superior discriminatory ability for predicting the pathological status of RLNs after neoadjuvant chemoradiotherapy. CRITICAL RELEVANCE STATEMENT: The nomogram presents a convenient and noninvasive method for evaluating the residual risk of RLNs after treatment for clinicians. It has the potential to provide guidance for a more precise lymph node dissection in patients with low residual risk. KEY POINTS: Accurate RLNs status prediction can lower local recurrence rates in esophageal cancer. The nomogram can be used for RLN pathological status prediction. The nomogram is convenient and noninvasive for the assessment of residual risk of RLNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.